Revolution Medicines reported Phase 3 data today that would have been science fiction five years ago.
Daraxonrasib, their multi-selective RAS(ON) inhibitor, hit both primary endpoints in the RASolute 302 trial for previously treated metastatic pancreatic cancer.
Median overall survival: 13.2 months versus 6.7 months for chemo. Hazard ratio of 0.40. p < 0.0001.
In pancreatic cancer, those numbers are seismic.
The standard of care in PDAC hasn’t meaningfully changed in over a decade. Gemcitabine plus nab-paclitaxel. FOLFIRINOX. Survival curves that barely move. Revolution Medicines, now a Merck subsidiary, may have finally broken that pattern. An NDA is planned, likely paired with a Commissioner’s National Priority Voucher, and full data will be presented at ASCO 2026.
But RevMed is big pharma now. The more interesting question for early-stage watchers: what does this data prove for the growing wave of startups and clinical-stage biotechs attacking RAS from completely different angles?
RAS was called “undruggable” for three decades.
Amgen cracked KRAS G12C with sotorasib. RevMed went broader with a multi-selective approach. And now a new generation is going after the pathway with modalities that didn’t exist when the target was written off.
RNAi. Oncolytic viruses. Pan-KRAS small molecules. Immune modulators.
Today’s data is their proof of concept too.
The early-stage RAS / PDAC pipeline
Jacobio Pharma — JAB-23E73
Small molecule · Pan-KRAS inhibitor (active + inactive states)
Silexion Therapeutics — SIL204
siRNA · Oncogenic KRAS silencing
Actuate Therapeutics — Elraglusib
Small molecule · GSK-3β inhibitor
Oncolytics Biotech — Pelareorep
Oncolytic virus · RAS-selective reovirus
Theriva Biologics — VCN-01
Oncolytic virus · Tumor-selective adenovirus
Five programs with recent traction that are benefiting from RAS target validation in PDAC
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you, contextualized and written directly to you, so you cut through the noise and immediately understand why it matters.
AstraZeneca already validated this thesis with their wallets. They paid Jacobio Pharma $100 million upfront, with up to $2 billion in total deal value, for JAB-23E73, a pan-KRAS inhibitor targeting multiple KRAS mutants in both active and inactive states. Phase 1/2 trials are running in China and the US.
Silexion Therapeutics is coming at KRAS from the RNA side entirely. SIL204 is an RNAi-based therapy that silences oncogenic KRAS drivers. Israel’s health ministry greenlit a Phase 2/3 trial in locally advanced pancreatic cancer, with initiation expected this quarter.
Actuate Therapeutics already has survival data of its own. Elraglusib, a GSK-3β inhibitor, showed median OS of 10.1 versus 7.2 months in a 286-patient randomized Phase 2 trial in first-line mPDAC. Different mechanism, same directional result. They’ve got Fast Track status and are heading toward a registration pathway this year.
Oncolytics Biotech and Theriva Biologics are coming from the oncolytic virus angle. Pelareorep (Oncolytics) selectively infects RAS-activated tumor cells and has a Fast Track designation for KRAS-mutant colorectal cancer. VCN-01 (Theriva) is an oncolytic adenovirus that cleared an End-of-Phase 2 FDA meeting for a pivotal trial in PDAC.
Three years ago, getting investors excited about another KRAS program required a very convincing pitch deck.
After today, Merck’s acquisition and a Phase 3 OS doubling have done a lot of that pitching for them.
